HONG KONG SAR – Media OutReach Newswire – 15 August 2025 – Yuexiu Transport (1052) announced its interim results 2025 and recorded revenue of RMB2.099 billion, representing a year-on-year increase of 14.9%. Profit attributable to shareholders was RMB361 million, an increase of 14.9%. The Company remains committed to maintaining a stable dividend policy with an interim dividend of HK$0.12 per share, equivalent to the payout ratio of 50%.
In November 2024, the Company acquired the Pinglin Expressway from its parent company. During the period, this project contributed approximately RMB256 million in toll revenue and approximately RMB42 million in profit attributable. This project is continuously bringing new momentum to the Company’s development and benefiting its long-term growth.
In the first half of 2025, the Company’s revenue and profit attributable to shareholders both realized double-digit growth. The Company’s 10 subsidiary projects, as a whole, recorded y-o-y growth in both average daily toll revenue and average daily toll traffic volume. The Company further reduced its total liabilities-to-total assets ratio, continued to optimise its financial structure and further extended its debt duration. The total liabilities-to-total assets ratio was 57.9%, dropped by 1.0 percentage point compared to the end of 2024. The weighted average financing rate was 2.57%, down by 0.48 percentage point compared to the first half of 2024.
The Company is committed to becoming a leading transport infrastructure asset management company in China. Guided by its “3331” development strategy, the Company will refine the three platforms (listed platform, REITs platform, incubation platform), enhance the three core abilities (investment ability, operation and maintenance and construction management ability, capital operation ability), and focus on three directions (expressway main business, key areas, expansion of related auxiliary businesses).
The Company will firmly grasp the strategic opportunities in expressway investment and mergers and acquisitions. Gaining its foothold in Guangdong, Hong Kong and Macau Greater Bay Area and in Central and Eastern China, the Company will expand its presence in the regions benefiting from urbanisation process and rapid industrialisation development. With the full utilisation of a model that features interaction among its three platforms, the Group continues to strengthen and expand its infrastructure business, with a particular focus on toll roads.

The issuer is solely responsible for the content of this announcement.

SEOUL, South Korea, Aug. 18, 2025 /PRNewswire/ — NEXEN TYRE, a leading global tyre manufacturer, has officially launched the ‘ROADIAN ATX’ in the Australian market, intensifying its efforts to tap into the country’s robust demand for high-inch tyres used on SUVs and Utes.

ROADIAN ATX IMAGE by NEXEN TYRE

Specifically engineered for both on- and off-road performance, the ROADIAN ATX is optimised for Australia’s diverse driving conditions – from desert highways and mountainous terrain to unpaved outback trails and coastal roads. The tyre features a wide contact patch and advanced rubber compound to maximise mileage and tread durability.

Key off-road technologies feature a 3D kerf design that enhances wet grip and a Three-Peak Mountain Snowflake (3PMSF) certification, validating its outstanding performance in snowy environments. Additional features such as stone ejectors and side biters prevent gravel retention and enhance traction on rocky surfaces, giving Australian drivers greater durability and confidence in challenging conditions.

The introduction of the ROADIAN ATX aligns with NEXEN TYRE’s broader strategy to cater to the growing preference for larger vehicles in Australia. The tyre is currently supplied as OE (Original Equipment) for iconic Jeep models including the Wrangler and Gladiator, reinforcing the brand’s global credibility and technological leadership.

To support its expansion, NEXEN TYRE AUSTRALIA is reinforcing its logistics and sales network across Australia. Following the opening of distribution centres in New South Wales (2023) and Victoria (2024), the company plans to open an additional logistics hub in Queensland in the second half of 2025. These investments aim to provide deliver efficiency and customer service across the eastern economic corridor, including Sydney, Melbourne, and Brisbane.

NEXEN TYRE AUSTRALIA is also amplifying its brand visibility through strategic sports marketing. Since October 2024, the company has been the official sponsor of Sydney FC, a leading club in Australia’s A-League. The partnership has significantly elevated the brand’s profile through LED signage, stadium displays, and virtual advertising during national broadcast matches and global streaming on Paramount+.

Furthermore, NEXEN TYRE AUSTRALIA actively engages with local fans through Sydney FC’s digital channels, including social media campaigns and newsletter placements, fostering stronger connections with Australian consumers.

“The ROADIAN ATX reflects our commitment understanding and meeting the unique needs of the Australian market,” said John Bosco (Hyeon Suk) Kim, CEO of NEXEN TYRE. “We will continue to build a strong local presence through product localisation, strategic partnerships, and an enhanced logistics framework.”

For more information, please visit http://www.nexentire.com/international/

SINGAPORE, Aug. 18, 2025 /PRNewswire/ — A new patient-led support group, the Neurofibromatosis Society (NFS) Singapore, has been recently registered with the Registry of Societies to provide emotional, psychosocial, and financial support for people affected by neurofibromatosis (NF) – a rare genetic condition that causes the development of tumours affecting nerves on the skin, brain, spinal cord and other parts of the body.

The group participated in the inaugural Regional Rare Skin Patients Support Group Summit 2025, jointly organised by the Asian Society of Pediatric Dermatology (ASPD) and the Rare Skin Conditions Society Singapore (RSCS). Titled “Beyond the Surface”, the summit saw representatives from across Southeast Asia coming together to discuss the needs of those living with rare skin conditions.

In Singapore, the number of individuals with NF is estimated to be in the hundreds, with NF Type 1 (NF1) being the most common diagnosis. NF1 manifests through symptoms such as multiple flat, light brown spots on the skin – known as “café au lait” spots – and soft bumps under or on the skin, called neurofibromas.^[1],[2] Patients are primarily treated at multi-disciplinary clinics established in recent years at the National Cancer Centre Singapore (NCCS) and KK Women’s and Children’s Hospital (KKH), where they can receive comprehensive care.

To further enhance patient support, healthcare providers from both institutions will work closely with NFS Singapore to provide guidance and care through a range of initiatives, including patient-led events, outreach and advocacy. Dr Nikki Fong, Consultant, Genetic Service at KKH, together with Clinical Assistant Professor Chiang Jianbang, Consultant, Cancer Genetics Service, NCCS, will be working closely with the group to guide their efforts and create a welcoming platform where NF patients can share their experiences and knowledge, helping them connect and build a strong support network.

“There is power in connection. Knowing you are not alone on this journey can be truly life-changing, whether you are a child or adult,” said Yessika Sutawijaya, 44, a co-founder of the group who was diagnosed at the age of eleven. “We hope that with NFS Singapore, we can help others on a similar journey find strength and live life fully, even in the face of challenges.”

As NF is often underdiagnosed, many patients live with feelings of isolation and a lack of information. This is often made worse by the social stigma and misunderstandings that come with visible changes in appearance, which can affect self-esteem and overall quality of life from childhood through adulthood.^[3],[4]

“Growing up with a rare, lifelong condition like NF can be especially challenging for children – not just physically, but emotionally and socially as well,” said Dr Fong. “Beyond medical treatment, young patients and their families need continual emotional and mental support. This group will play a pivotal role in addressing those unseen needs, complementing the clinical journey with peer and psychological support.”

Lai Chee Chong, 45, another co-founder of NFS Singapore, reflected on his own childhood, “As a child, living with NF affected my self-confidence. I found it difficult to make friends because people thought my condition was contagious. Now, I want to help create more awareness on NF.”

NFS Singapore was established in close collaboration with organisations such as RSCS, and with the support of corporates such as biopharmaceutical company AstraZeneca.

Ms Kim Suyeon, Country President, AstraZeneca Singapore, said, “AstraZeneca is committed to supporting an initiative that puts patients with NF at the heart of everything, ensuring they feel seen, heard, and supported beyond clinical care.”

HONG KONG, Aug. 18, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) announces encouraging preclinical efficacy results for ASC47, a first-in-class muscle-preserving weight loss drug candidate for the treatment of obesity, in combination with ASC31, its in-house developed GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual targeting peptide agonist drug candidate.

ASC31 is an in-house discovered and developed novel peptide agonist targeting both GLP-1R and GIPR, which demonstrated a favorable pharmacokinetic profile in non-human primates as well as promising in vitro activities and in vivo efficacy in the diet-induced obese (DIO) mice. ASC31 is part of Ascletis’ discovery efforts to apply its Ultra-Long-Acting Platform (ULAP) to in-house discovered novel subcutaneously (SQ) injectable peptides and oral peptides.

ASC47 is an adipose-targeted, once-monthly SQ injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue.

The objective of the DIO mouse study was to compare efficacy in weight loss of a low dose of ASC47 (9 mg/kg, SQ) combined with ASC31 (3 nmol/kg, SQ) to a low dose of ASC47 (9 mg/kg, SQ) combined with tirzepatide (3 nmol/kg, SQ). The treatment duration was 14 days. Results showed that the combination of ASC47 with ASC31 was 17.6% more effective (p=0.02) compared to the combination of ASC47 with tirzepatide, with an average total body weight reduction of 44.8% versus 38.1%, respectively.

“The significant weight reduction demonstrated with the combination of our novel GLP-1R/GIPR peptide agonist, ASC31, and our THRβ agonist, ASC47, in this animal model suggests the potential for meaningful differentiation compared to currently marketed obesity treatments as well as product candidates in development,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “Ascletis is developing a strong pipeline of small molecules and peptides for the potential treatment of obesity, and we look forward to providing additional development updates moving forward.”

For more information, please visit www.ascletis.com.

According to a newly released report from the Ministry of Agriculture and Environment, import value in July alone was estimated at close to $400 million.

Dairy products posted the sharpest growth, reaching more than $860 million, while meat and post-slaughter by-products accounted for over $1 billion. The surge was driven largely by rising domestic demand, especially as volatile feed prices pushed local meat costs to levels that are hard to compete with imports.

The Southeastern Livestock Association said that high production costs at home stem from dependence on imported feed ingredients and small-scale farming, while deeper market integration has made it easier for foreign products to reach Vietnamese consumers.

“Against this backdrop, the domestic livestock sector is being forced to adapt by improving productivity, upgrading processes, and diversifying product lines,” a representative of the Southeastern Livestock Association said.

However, the association also stressed that for competition to be truly fair, tighter control over imported meat quality is essential. This is particularly important given that African swine fever remains present, raising the risk of substandard meat entering the market if oversight is lacking.